What is a CXDMO?
CXDMO is an umbrella term for CRDMOs (Contract Research, Development and Manufacturing Organizations) and related pharmaceutical outsourcing business models. It spans the full value chain — from drug discovery and process development through preclinical and clinical research to commercial manufacturing — and is the hub connecting biotech, pharma and capacity in the innovation ecosystem.
With the new-molecule wave in ADC/XDC, the boom in peptides and oligonucleotides (TIDES), and the geographic restructuring of global capacity, the CXDMO industry is being reshaped: Chinese leaders compete on cost, speed and integration, while Western giants respond with M&A and refocusing.
What We Cover
CXDMO (cxdmo.com) is an independent industry news portal tracking:
- The WuXi Group: WuXi AppTec (small-molecule CRDMO), WuXi Biologics (large-molecule CRDMO), WuXi XDC (ADC/XDC CRDMO)
- Domestic CXDMOs: Pharmaron, Asymchem, Porton Pharma / Porton Bio
- Global Frontier: Samsung Biologics, Lonza
Coverage spans financial results, capacity expansion, M&A and integration, strategic partnerships, regulatory qualifications and industry trend analysis.
Sources & Updates
Content is compiled from company press releases, listed-company announcements and reporting by mainstream financial and industry media, with the original source cited on every story. Content from closed channels such as WeChat official accounts is captured via equivalent public press releases and authoritative republications.
The site is static by architecture, generated by a local build script, and suited to static hosting platforms such as Cloudflare Pages.
Disclaimer
All content is for industry reference only and does not constitute investment advice. Data and facts are subject to official company disclosures. For copyright concerns, please reach out via the site pages.